background
respiratori
infect
common
reason
hospit
admiss
associ
enorm
econom
burden
due
signific
morbid
mortal
wide
spectrum
microbi
agent
underli
patholog
render
diagnosi
respiratori
infect
challeng
molecular
diagnost
offer
advantag
current
serolog
culturebas
method
term
sensit
coverag
handson
time
time
result
object
studi
aim
compar
clinic
perform
three
commerci
kit
respiratori
viral
detect
studi
design
perform
filmarray
respiratori
panel
anyplexii
argen
compar
use
clinic
respiratori
sampl
n
compris
nasopharyng
swab
univers
transport
medium
utm
endotrach
aspir
base
common
overlap
target
across
platform
influenza
equivoc
nosubtyp
sampl
filmarray
compar
laboratorydevelop
influenza
ab
test
overal
perform
three
platform
appear
compar
regard
sensit
specif
detect
coinfect
distinguish
influenza
noninfluenza
case
equivoc
nosubtyp
sampl
filmarray
mostli
repres
weak
influenza
laboratorydevelop
test
lower
respiratori
tract
sampl
compar
finalrun
successr
discordantr
compar
utm
coronaviru
target
anyplexii
detect
expect
test
volum
would
main
determin
select
platform
among
platform
filmarray
autom
lowestthroughput
highest
reagent
cost
respiratori
infect
one
common
reason
hospit
admiss
identif
caus
agent
often
omit
limit
pathogen
easili
detect
direct
antigen
test
howev
reliabl
diagnosi
respiratori
infect
import
therapi
implement
isol
measur
better
use
antimicrobi
therapi
epidemiolog
data
laboratori
use
prescrib
prophylact
treatment
risk
patient
alert
new
season
spread
pathogen
direct
fluoresc
antibodi
test
viral
cultur
time
consum
demand
signific
expertis
perform
test
interpret
test
result
hand
rapid
antigen
test
appear
lack
sensit
detect
influenza
respiratori
syncyti
viru
rsv
report
sensit
low
respect
nucleic
acid
detect
test
respiratori
viru
assay
gain
popular
due
quick
turnaroundtim
propens
multiplex
autom
fda
clear
four
molecular
multiplex
respiratori
panel
name
filmarray
rp
respiratori
panel
biofir
diagnost
salt
lake
citi
ut
esensor
rvp
respiratori
viral
panel
genmark
dx
carlsbad
ca
luminex
xtag
luminex
xtag
rvp
fast
luminex
molecular
diagnost
austin
tx
platform
abl
detect
target
simultan
report
sensit
specif
respect
filmarray
rp
farp
autom
requir
preextract
addit
test
three
bacteri
agent
detect
http
receiv
januari
receiv
revis
form
may
accept
juli
three
platform
name
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
farp
melt
curvebas
realtim
pcr
rtpcr
method
wherebi
amplif
occur
two
step
st
step
enrich
target
nucleic
acid
sampl
multiplex
reaction
step
amplifi
target
multipl
miniatur
individu
well
contain
singl
specif
primerpair
nucleic
acid
extract
distribut
nucleic
acid
well
pcr
amplif
fulli
autom
integr
occur
singleus
pouch
anyplexii
seegen
south
korea
altern
fdaapprov
integr
platform
requir
preextract
prerevers
transcript
run
common
rtpcr
platform
biorad
hercul
ca
thermo
fisher
scientif
waltham
util
proprietari
toce
technolog
achiev
simultan
detect
melt
curv
viral
target
twotub
reaction
argen
realtim
pcr
assayrespiratori
rang
biomerieux
franc
compat
major
extract
platform
realtim
pcr
system
well
variou
sampl
type
argen
pcr
kit
valid
exhibit
good
analyt
sensit
specif
thu
repres
rapid
reliabl
test
detect
virus
bacteria
caus
respiratori
infect
turnaround
time
assay
includ
extract
within
h
object
studi
compar
clinic
perform
use
actual
clinic
respiratori
sampl
two
multiplex
strategi
repres
farp
version
anyplexii
version
convent
twoplex
rtpcr
kit
repres
respiratori
viru
assay
argen
biomerieux
franc
rang
research
studi
protocol
submit
singhealth
centralis
institut
review
board
cirb
ref
exempt
review
base
natur
studi
total
specimen
compris
nasopharyng
swab
specimen
univers
transport
medium
utm
copan
itali
endotrach
aspir
ett
specimen
collect
symptomat
patient
august
march
first
studi
specimen
collect
prospect
sequenti
order
remain
specimen
compris
farp
posit
univers
transport
medium
utm
specimen
respiratori
aspir
posit
neg
specimen
distribut
microorgan
detect
sampl
use
studi
shown
supplement
tabl
farp
anyplexii
argen
assay
compris
adenovirusbocaviru
coronaviruspiv
influenza
ainfluenzab
rsv
mpv
rhinovirusenteroviru
highli
similar
target
bocaviru
farp
bacteri
target
b
pertussi
c
pneumonia
pneumonia
compar
bocaviru
cover
farp
bacteri
agent
cover
anyplexii
argen
coronaviru
parainfluenza
detect
argen
kit
subtyp
report
group
farp
detect
subtyp
four
coronaviru
subtyp
anyplexii
cover
subtyp
three
influenza
subtyp
anyplexii
argen
rhinovirusenteroviru
rsv
report
group
farp
argen
contrast
anyplexii
distinguish
rhinoviru
enteroviru
could
subtyp
rsv
rsv
rsv
b
qualiti
control
assay
valid
result
interpret
perform
accord
individu
manufactur
instruct
anyplexii
argen
microbi
nucleic
acid
extract
use
viru
mini
kit
qiagen
singapor
qiagen
singapor
autom
sampl
prepar
platform
sampl
extract
volum
elut
volum
fa
perform
extract
nucleic
acid
amplif
platform
utm
sampl
use
directli
farp
extract
respiratori
aspir
underw
preprocess
use
dunk
swirl
method
utm
prior
nucleic
acid
extract
briefli
sputum
sampl
dilut
mix
equal
volum
steril
water
steril
swab
dunk
sampl
withdrawn
swirl
steril
water
swab
remov
solut
use
test
anyplexii
argen
rtpcr
run
carri
use
biorad
rotorgen
qiagen
respect
farp
automat
interpret
show
result
target
detect
detect
invalid
farp
influenza
result
equivoc
subtyp
specimen
test
inhous
influenza
ab
multiplex
qpcr
assay
detect
preval
influenza
viru
subtyp
influenza
viru
subtyp
influenza
b
viru
sampl
equivoc
subtyp
farp
confirm
argen
anyplexii
true
posit
low
viral
load
inhous
pcr
assay
use
extend
refer
test
farp
equivoc
subtyp
sampl
argen
assay
cycl
threshold
denot
presenc
target
organ
sampl
accord
manufactur
instruct
anyplexii
assay
melt
curv
call
posit
neg
result
accord
kit
instruct
three
platform
result
valid
run
use
calcul
comparison
studi
approach
extend
composit
refer
use
interpret
result
true
posit
defin
posit
two
three
platform
compar
facilit
comparison
case
target
report
group
identif
correct
group
would
consid
concord
case
compar
anoth
assay
may
provid
specif
identif
exampl
detect
influenza
anyplexii
argen
detect
influenza
filmarray
specimen
would
consid
concord
result
result
multipleposit
sampl
group
respect
target
sensit
specif
calcul
perform
farp
method
differ
sampl
type
utm
vs
ett
term
sensit
specif
evalu
accomplish
compar
result
obtain
use
farp
composit
gold
standard
two
sampl
type
concord
result
farp
composit
gold
standard
ie
posit
neg
consid
match
twotail
fisher
exact
test
use
assess
signific
differ
correct
diagnosi
use
farp
method
composit
gold
standard
refer
two
sampl
type
pvalu
less
consid
statist
signific
first
specimen
prospect
collect
sequenti
order
reflect
actual
clinic
distribut
sampl
sent
laboratori
specimen
posit
farp
common
virus
detect
human
rhinovirusenteroviru
influenza
b
rsv
sampl
detect
dualinfect
subsequ
first
specimen
sampl
collect
select
purpos
select
addit
posit
target
compar
test
final
collect
compris
posit
sampl
repres
target
cover
farp
except
influenza
one
posit
specimen
collect
coronaviru
parainfluenza
viru
target
repres
sampl
supplement
tabl
specimen
posit
target
singl
specimen
posit
target
influenza
specimen
studi
cover
categori
influenza
result
except
subtyp
categori
overal
perform
three
platform
compar
sensit
specif
rang
respect
discord
rate
farp
argen
anyplexii
also
similar
respect
discord
case
random
across
target
promin
shortcom
specif
associ
platform
test
tabl
among
three
platform
argen
falseneg
associ
lowest
sensit
highest
specif
farp
associ
highest
sensit
lowest
specif
tabl
differ
statist
differ
p
specif
individu
assay
three
platform
tabl
farp
lowest
sensit
detect
adenoviru
argen
lowest
sensit
detect
rhinoenteroviru
rsv
anyplexii
lowest
sensit
influenza
two
dualposit
sampl
sequenti
collect
sampl
dualposit
sampl
entir
test
panel
one
discord
case
observ
cov
rsv
farp
cov
argen
anyplexii
suggest
dual
posit
sampl
diagnos
accur
use
farp
argen
anyplexii
specimen
repres
influenza
subtyp
equivoc
result
report
farp
sampl
test
use
compar
platform
compar
inhous
qpcr
test
test
presenc
influenza
influenza
b
three
subtyp
sampl
influenza
posit
argen
ctvalu
anyplexii
inhous
test
ctvalu
ctvalu
argen
inhous
test
compar
four
equivoc
sampl
influenza
posit
argen
inhous
test
anyplexii
neg
two
sampl
two
influenza
equivoc
sampl
consid
posit
farp
equivoc
sampl
ctvalu
suggest
equivoc
sampl
may
weak
posit
sampl
nosubtyp
sampl
may
also
moderatetoweak
tabl
summari
discord
case
studi
fn
falseneg
fp
falseposit
sake
simplic
entri
repres
replac
instead
posit
sampl
among
utm
sampl
sampl
test
posit
farp
turn
posit
composit
gold
standard
sampl
test
neg
farp
turn
neg
composit
gold
standard
henc
accord
definit
three
discord
resultstwo
fals
posit
one
fals
neg
utm
sampl
translat
sensit
specif
farp
method
use
utm
sampl
among
ett
sampl
sampl
test
posit
farp
turn
posit
composit
gold
standard
sampl
test
neg
farp
turn
neg
composit
gold
standard
henc
two
discord
resultson
fals
posit
one
fals
neg
ett
sampl
translat
sensit
specif
farp
method
use
ett
sampl
statist
analysi
show
utm
versu
ett
sampl
correctli
classifi
percentag
differ
statist
signific
p
fisher
exact
test
wide
rang
diagnost
kit
respiratori
pathogen
emerg
address
american
fdaapprov
european
ceivd
market
kit
vari
wide
term
extens
target
coverag
throughput
degre
autom
among
nonfda
approv
platform
respifind
pathofind
seeplex
seegen
magicplex
rv
panel
seegen
clart
pneumovir
genomica
resplex
ii
panel
qiagen
compar
extens
report
sensit
rang
low
albeit
excel
specif
pathogen
among
fdaapprov
platform
perform
farp
luminex
xtag
rvp
luminex
xtag
rvp
fast
esensor
rvp
investig
sensit
rang
luminex
xtag
rvp
fast
esensor
rvp
specif
high
assay
farp
overal
sensit
substanti
lower
sensit
note
detect
adenoviru
compar
fewer
evalu
anyplexii
compar
studi
assay
report
overal
sensit
compar
studi
farp
anyplexii
argen
assay
note
compar
sensit
specif
respect
comparison
studi
anyplexii
seeplex
seegen
xtag
rvp
overal
sensit
better
xtag
rvp
howev
improv
sensit
rhinoviru
requir
studi
farp
anyplexii
sensit
rhinovirusenteroviru
better
argen
henc
lack
sensit
toward
rhinoviru
previous
report
observ
studi
sensit
farp
adenoviru
concern
origin
version
kit
abl
detect
sever
adv
serotyp
modifi
version
sensit
improv
retrospect
studi
prospect
studi
howev
still
one
serotyp
serotyp
remain
undetect
perform
adenoviru
test
still
lower
compar
inhous
assay
studi
sensit
farp
adv
compar
report
earlier
respiratori
aspir
specif
interest
diagnosi
communityacquir
pneumonia
howev
farp
fdaclear
test
nasopharyng
swab
specimen
transport
utm
contrast
respiratori
aspir
consid
accept
sampl
argen
anyplexii
ceivd
two
previou
studi
evalu
farp
larg
number
bronchoalveolar
lavag
bal
specimen
support
util
respiratori
aspir
farp
studi
final
runqc
failur
associ
use
respiratori
aspir
farp
furthermor
signific
differ
percentag
match
compar
farp
composit
gold
standard
utm
ett
sampl
type
henc
earlier
studi
suggest
respiratori
aspir
accept
sampl
type
farp
sampl
adv
influenza
b
rsv
target
repres
sampl
size
rang
although
sampl
adv
influenza
b
rsv
desir
collect
period
prolong
similarli
influenza
equivoc
nosubtyp
sampl
desir
similarli
respiratori
aspir
ett
sputum
bal
poorli
repres
repres
one
coronaviru
posit
sampl
henc
categori
well
repres
anoth
shortcom
use
posit
least
two
platform
refer
result
calcul
sensit
specif
henc
assay
greater
sensit
assay
test
would
result
reduc
specif
final
platform
compar
herein
multiplex
assay
argen
duplexassay
closest
convent
qpcr
assay
ideal
target
compar
individu
qpcr
assay
practic
due
lack
laboratori
develop
test
ldt
everi
target
well
financi
constraint
one
shortcom
filmarray
despit
short
turnaround
time
h
one
sampl
could
process
per
run
platform
higher
sampl
throughput
sampl
despit
longer
turnaround
time
h
xtag
h
xtag
fast
h
esensor
h
anyplexii
anyplexii
argen
thu
higher
throughput
gear
toward
batch
test
low
complex
filmarray
suit
ondemand
analysi
requir
minimum
handson
time
sinc
filmarray
perform
compar
anyplexii
laboratori
requir
turnov
workflow
consider
would
major
determin
select
platform
screen
respiratori
agent
also
note
filmarray
also
highest
reagent
cost
among
autom
platform
worth
note
three
chosen
technolog
employ
studi
design
differ
laboratori
purpos
biofir
system
regard
workflow
clearli
suitabl
emerg
point
care
test
excel
time
result
seegen
anyplexii
altern
allplex
onestep
rtpcr
fit
well
routin
activ
involv
batch
sampl
test
daili
basi
argen
solut
offer
quit
similar
featur
ad
advantag
test
panel
may
adapt
focu
particular
organ
influenza
rsv
epidem
period
depend
ongo
epidemiolog
respiratori
infect
demonstr
compar
clinic
perform
three
commerci
kit
respiratori
viral
detect
name
filmarray
respiratori
panel
rp
anyplexii
argen
use
archiv
clinic
respiratori
sampl
base
common
overlap
target
across
platform
extens
studi
larger
sampl
size
repres
differ
viral
categori
requir
evalu
platform
perform
higher
resolut
author
declar
conflict
interest
supplementari
materi
relat
articl
found
onlin
version
doi
http
